Q current report, 14 December 2022

Business Context and Reporting Period

This Form 8-K reports on the results of the 2022 Annual Meeting of Stockholders held by MyMD Pharmaceuticals, Inc. on December 14, 2022. The company is incorporated in New Jersey and its common stock trades on The Nasdaq Capital Market under the symbol MYMD.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.

Material Changes and Voting Results

At the Annual Meeting, 30,840,727 votes were present in person or by proxy. Two matters were voted upon:

  • Election of Directors: All six nominees were elected to one-year terms. Notable voting statistics include:
Nominee Votes For Votes Withheld Broker Non-Votes
Chris Chapman 19,923,914 287,893 10,628,920
Craig Eagle 20,115,061 96,746 10,628,920
Christopher C. Schreiber 20,066,262 145,545 10,628,920
Joshua Silverman 18,720,289 1,491,518 10,628,920
Jude Uzonwanne 17,816,077 2,395,730 10,628,920
Bill J. White 20,157,803 54,004 10,628,920
  • Ratification of Auditors: The appointment of Morison Cogen LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2022, was ratified.
Category Votes
For 30,778,525
Against 40,617
Abstaining 21,585

Guidance, Outlook, and Risks

The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The report states that no other matters were considered or voted upon at the meeting.

Important Facts for Investors to Verify

  • Verify the significant number of broker non-votes (10,628,920) relative to the total votes present, which indicates a large portion of shares were held in street name without voting instructions on the director election.
  • Confirm the specific terms of the newly elected directors, which expire at the 2023 annual meeting.
  • Review the definitive proxy statement filed on October 26, 2022, for detailed background on the director nominees and auditor ratification.